{"entity":{"id":"nct05179889","kind":"trial","name":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","aka":[],"tldr":"A phase 2/3 trial of fOLFIRINOX / mFOLFIRINOX and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Chungnam National University Hospital, now recruiting.","summary":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer is a phase 2/3, randomised interventional study registered as NCT05179889 by Chungnam National University Hospital, with a registry enrolment figure of 308 participants, started 2021-07-06 and due to reach its primary completion in 2028-07-05. Interventions recorded: mFOLFIRINOX; mFOLFOX 6. Conditions listed: Colon Cancer Stage III. Primary outcome: Disease free survival (DFS). Colorectal eligibility wording from the registry: \"Pathologically confirmed high-risk stage III colon adenocarcinoma (pT4N1 or pTanyN2)\". Sites: South Korea. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05179889","url":"https://clinicaltrials.gov/study/NCT05179889"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["folfirinox","folfox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05179889","phase":"2/3","setting":"mFOLFIRINOX Versus mFOLFOX 6 as Adjuvant Treatment for High Risk Stage III (pT4N1/2 or pTanyN2) Colon Cancer: Multicenter, Open Labeled, Randomized, Phase II Study","sponsor":"Chungnam National University Hospital","enrolled":308,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05179889/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}